1 week Ago By Defense World Staff
JPMorgan Chase & Co. raised its stake in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 147.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The institutional investor owned 889,472 shares of the company’s stock after purchasing an additional 529,962 shares during the quarter. JPMorgan Chase & Co. owned 0.
55% of Alkermes worth $25,581,000 as of its most recent filing with the Securities and Exchange Commission. Other large investors also recently modified their holdings of the company. American Century Companies Inc.
grew its position in Alkermes by 6.5% in the fourth quarter. American Century Companies Inc.
now owns 3,450,707 shares of the company’s stock valued at $99,242,000 after acquiring an additional 209,740 shares during the period. Artisan Partners Limited Partnership increased its position in shares of Alkermes by 2.6% during the 4th quarter.
Artisan Partners Limited Partnership now owns 1,988,796 shares of the company’s stock worth $57,198,000 after purchasing an additional 50,470 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Alkermes by 2.
5% during the 4th quarter. Principal Financial Group Inc. now owns 899,764 shares of the company’s stock valued at $25,877,000 after purchasing an additional 21,821 shares during the last quarter.
Frazier Life Sciences Management L.P. bought a new stake in Alkermes during the third quarter worth about $16,126,000.
Finally, Rhumbline Advisers grew its stake in Alkermes by 0.4% during the fourth quarter. Rhumbline Advisers now owns 464,714 shares of the company’s stock worth $13,365,000 after buying an additional 1,683 shares during the last quarter.
95.21% of the stock is currently owned by institutional investors. Insider Activity at AlkermesIn related news, EVP Craig C.
Hopkinson sold 144,419 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.
07. Following the completion of the sale, the executive vice president now owns 57,875 shares in the company, valued at $2,056,298.75.
This represents a 71.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
4.89% of the stock is currently owned by corporate insiders. Analysts Set New Price TargetsALKS has been the topic of several recent analyst reports.
Deutsche Bank Aktiengesellschaft boosted their target price on Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, March 27th.
Royal Bank of Canada began coverage on Alkermes in a report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 target price on the stock.
StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. HC Wainwright restated a “neutral” rating and issued a $46.
00 price objective on shares of Alkermes in a research report on Thursday, February 13th. Finally, UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and upped their target price for the stock from $21.00 to $38.
00 in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.
com, the company currently has an average rating of “Moderate Buy” and an average target price of $39.38.Read Our Latest Report on ALKSAlkermes Stock PerformanceShares of Alkermes stock opened at $28.
19 on Wednesday. The firm has a fifty day moving average of $33.43 and a two-hundred day moving average of $30.
46. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 12.
99, a PEG ratio of 2.20 and a beta of 0.39.
Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.45.
Alkermes (NASDAQ:ALKS – Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.
81 by $0.11. Alkermes had a return on equity of 30.
80% and a net margin of 23.57%. As a group, research analysts forecast that Alkermes plc will post 1.
31 EPS for the current fiscal year. Alkermes Company Profile (Free Report)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured StoriesFive stocks we like better than AlkermesMost active stocks: Dollar volume vs share volumeTariff-Proof Stocks: 3 Big Bargains With Huge Upside PotentialThe Top 3 Healthcare Dividend Stocks to Buy and HoldQualcomm Breaks Down But RSI Signals It’s Severely OversoldBest Aerospace Stocks Investing Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy.
